B.R. Haugen, E.K. Alexander, K.C. Bible et al. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 26(1), 1–133 (2016). https://doi.org/10.1089/thy.2015.0020

Article  PubMed  PubMed Central  Google Scholar 

AIOM. Linee guida AIOM tumori della tiroide. Aiom. Published online 2021.

K.A. Araque, S. Gubbi, J. Klubo-Gwiezdzinska, Updates on the management of thyroid cancer. Horm. Metab. Res. 52(8), 562–577 (2020). https://doi.org/10.1055/a-1089-7870

Article  CAS  PubMed  PubMed Central  Google Scholar 

C. Christofer Juhlin, O. Mete, Z.W. Baloch, The 2022 WHO classification of thyroid tumors: novel concepts in nomenclature and grading. Endocr. Relat. Cancer 30(2), e220293 (2023). https://doi.org/10.1530/ERC-22-0293

Article  CAS  PubMed  Google Scholar 

S. Filetti, C. Durante, D. Hartl et al. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 30(12), 1856–1883 (2019). https://doi.org/10.1093/annonc/mdz400

Article  CAS  PubMed  Google Scholar 

L. Boucai, M. Zafereo, M.E. Cabanillas, Thyroid cancer: a review. JAMA 331(5), 425–435 (2024). https://doi.org/10.1001/jama.2023.26348

Article  CAS  PubMed  Google Scholar 

N. Pajamäki, S. Metso, T. Hakala, T. Ebeling, H. Huhtala, E. Ryödi, J. Sand, A. Jukkola-Vuorinen, P. Kellokumpu-Lehtinen, JP, Long-term cardiovascular morbidity and mortality in patients treated for differentiated thyroid cancer. Clin. Endocrinol. 88(2), 303–310 (2018). https://doi.org/10.1111/ijlh.12426

Article  Google Scholar 

S.R. Shih, W.Y. Chiu, T.C. Chang, C.H. Tseng, Diabetes and thyroid cancer risk: literature review. J. Diabetes Res. 2012(1), 20–23 (2012). https://doi.org/10.1155/2012/578285

J.P. Bilezikian, A.A. Khan, S.J. Silverberg et al. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the fifth international workshop. J. Bone Miner. Res. 37(11), 2293–2314 (2022). https://doi.org/10.1002/jbmr.4677

Article  PubMed  Google Scholar 

M.D. Walker, S.J. Silverberg, Primary hyperparathyroidism. Nat. Rev. Endocrinol. 14(2), 115–125 (2018). https://doi.org/10.1038/nrendo.2017.104

Article  CAS  PubMed  Google Scholar 

J.P. Bilezikian, Primary hyperparathyroidism. J. Clin. Endocrinol. Metab. 103, 3993–4004 (2018). https://doi.org/10.1016/B978-0-12-801238-3.65217-0

Article  PubMed  PubMed Central  Google Scholar 

N.E. Cusano, S.J. Silverberg, J.P. Bilezikian, Normocalcemic primary hyperparathyroidism. J. Clin. Densitom. 16(1), 33–39 (2013). https://doi.org/10.1016/j.jocd.2012.12.001

S.J. Brown, M.D. Ruppe, L.S. Tabatabai, The parathyroid gland and heart disease. Methodist Debakey Cardiovasc. J 13(2), 49–54 (2017). https://doi.org/10.14797/mdcj-13-2-49

Article  PubMed  PubMed Central  Google Scholar 

S. Goswami, S. Ghosh, Hyperparathyroidism: cancer and mortality. Indian J. Endocrinol. Metab. 16(8), 217 (2012). https://doi.org/10.4103/2230-8210.104042

Article  Google Scholar 

J.T. Adler, R.S. Sippel, S. Schaefer, H. Chen, Surgery improves quality of life in patients with “mild” hyperparathyroidism. Am. J. Surg. 197(3), 284–290 (2009). https://doi.org/10.1016/j.amjsurg.2008.09.009

Article  PubMed  Google Scholar 

E. Ambrogini, F. Cetani, L. Cianferotti et al. Surgery or surveillance for mild asymptomatic primary hyperparathyroidism: a prospective, randomized clinical trial. J. Clin. Endocrinol. Metab. 92(8), 3114–3121 (2007). https://doi.org/10.1210/jc.2007-0219

Article  CAS  PubMed  Google Scholar 

L. Vera, M. Accornero, M. Dolcino, S. Oddo, M. Giusti, Five-year longitudinal evaluation of mild primary hyperparathyroidism—medical treatment versus clinical observation. Endokrynol. Pol. 65(6), 456–463 (2014). https://doi.org/10.5603/EP.2014.0063

Article  CAS  PubMed  Google Scholar 

L. Dell’Erba, S. Baldari, N. Borsato et al. Retrospective analysis of the association of nodular goiter with primary and secondary hyperparathyroidism. Eur. J. Endocrinol. 145(4), 429–434 (2001). https://doi.org/10.1530/eje.0.1450429

Article  PubMed  Google Scholar 

T. Masatsugu, H. Yamashita, S. Noguchi et al. Significant clinical differences in primary hyperparathyroidism between patients with and those without concomitant thyroid disease. Surg. Today 35(5), 351–356 (2005). https://doi.org/10.1007/s00595-004-2952-9

Article  PubMed  Google Scholar 

G. Vargas-Ortega, L. Balcázar-Hernández, B. González-Virla et al. Symptomatic primary hyperparathyroidism as a risk factor for differentiated thyroid cancer. J. Thyroid Res. 2018, 1–6 (2018). https://doi.org/10.1155/2018/9461079

Article  CAS  Google Scholar 

R.P. Walker, E. Paloyan, The relationship between Hashimoto’s thyroiditis, thyroid neoplasia, and primary hyperparathyroidism. Otolaryngol. Clin. N. Am. 23(2), 291–302 (1990).

Article  CAS  Google Scholar 

S.Y. Morita, H. Somervell, C.B. Umbricht, A.P. Dackiw, M. Zeiger, Evaluation for concomitant thyroid nodules and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Surgery 144(6), 862–866 (2008). https://doi.org/10.1016/j.surg.2008.07.029

M.C. Wright, K. Jensen, H. Mohamed et al. Concomitant thyroid disease and primary hyperparathyroidism in patients undergoing parathyroidectomy or thyroidectomy. Gland Surg. 6(4), 368–374 (2017). https://doi.org/10.21037/gs.2017.04.01

Article  PubMed  PubMed Central  Google Scholar 

B. Wagner, S. Begic-Karup, W. Raber, B. Schneider, W.V.H. Waldhäusl, Prevalence of primary hyperparathyroidism in 13387 patients with thyroid diseases, newly diagnosed by screening of serum calcium. Exp. Clin. Endocrinol. Diabetes 107(7), 457–461 (1999). https://doi.org/10.1055/s-0029-1212138

S. Murray, S. rebecca, H.C. FACS, The incidence of concomitant hyperparathyroidism in patients with thyroid disease requiring surgery. J. Surg. Res. 178(1), 264–267 (2013). https://doi.org/10.1016/j.jss.2012.03.008

Article  Google Scholar 

S.J. Silverberg, B.L. Clarke, M. Peacock et al. Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the fourth international workshop. J. Clin. Endocrinol. Metab. 99(10), 3580–3594 (2014). https://doi.org/10.1210/jc.2014-1415

Article  CAS  PubMed  PubMed Central  Google Scholar 

L. Castelo-Branco, A. Pellat, D. Martins-Branco, A. Valachis, J.W.G. Derksen, K.P.M. Suijkerbuijk, U. Dafni, T. Dellaporta, A. Vogel, A. Prelaj, R.H.H. Groenwold, H. Martins, R. Stahel, J. Bliss, J. Kather, N. Ribelles, F. Perrone, P.S. Hall, R. Dienstmann, C.M. Booth, G. Pentheroudakis, S. Delaloge, M. Koopman, ESMO Guidance for Reporting oncology real-World evidence (GROW). Ann. Oncol. 34(12), 1097–1112 (2023).

F. Vescini, G. Borretta, I. Chiodini, et al. Linea guida sulla gestione terapeutica dell’iperparatiroidismo primario sporadico nell’adulto—Istituto superiore di sanità 2023. Published online 2023:1–22.

P.L. Ogburn, P.M. Black, Primary hyperparathyroidism and papillary adenocarcinoma of the thyroid; report of four cases. Proc. Staff Meet Mayo Clin. 31(10), 295–298 (1956).

CAS  PubMed  Google Scholar 

P. Yazici, M. Mihmanli, E. Bozdag, N. Aygun, M. Uludag, Incidental finding of papillary thyroid carcinoma in the patients with primary hyperparathyroidism. Eurasian J. Med. 47(3), 194–198 (2015). https://doi.org/10.5152/eurasianjmed.2015.119

Article  PubMed  PubMed Central  Google Scholar 

L..A. Burmeister, M. Sandberg, S.E. Carty, C.G. Watson. Thyroid carcinoma found at parathyroidectomy: association with primary, secondary, and tertiary hyperparathyroidism. Cancer 79(8), 1611–1616 (1997). https://doi.org/10.1002/(sici)1097-0142(19970415)79:83.0.co;2-#

C. Jeong, H.I. Kwon, H. Baek et al. Association of hyperparathyroidism and papillary thyroid cancer: a multicenter retrospective study. Endocrinol. Metab. 35(4), 925–932 (2021). https://doi.org/10.3803/ENM.2020.725

Article  Google Scholar 

C.Y. Tsai, S.T. Chen, C. Hsueh, Y.S. Lin, J.D. Lin, Long-term therapeutic outcomes of papillary thyroid carcinoma with concomitant hyperparathyroidism: a single center case-control study. Biomed. J. 43(1), 53–61 (2020). https://doi.org/10.1016/j.bj.2019.05.010

Article  PubMed  PubMed Central  Google Scholar 

G. Scerrino, N.C. Paladino, G. Orlando et al. The nexus of hyperparathyroidism and thyroid carcinoma: insights into pathogenesis and diagnostic challenges—a narrative review. J. Clin. Med. 13(1), 1–12 (2024). https://doi.org/10.3390/jcm13010147

Article  CAS  Google Scholar 

M.F. McCarty, Parathyroid hormone may be a cancer promoter—an explanation for the decrease in cancer risk associated with ultraviolet light, calcium, and Vitamin D. Med. Hypotheses 54(3), 475–482 (2000). https://doi.org/10.1054/mehy.1999.0880

Article  CAS  PubMed  Google Scholar 

A.S. Geara, M.R. Castellanos, C. Bassil et al. Effects of parathyroid hormone on immune function. Clin. Dev. Immunol. 2010, 418695 (2010). https://doi.org/10.1155/2010/418695

Article  CAS  PubMed  PubMed Central